Targeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of Tazemetostat.
EZH2 mutation
follicular lymphoma
tazemetostat
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
12
2021
accepted:
12
02
2022
entrez:
7
3
2022
pubmed:
8
3
2022
medline:
8
3
2022
Statut:
epublish
Résumé
The management of follicular lymphoma (FL) in the relapsed and refractory setting is challenging and an area of ongoing investigation. Epigenetic dysregulation has recently been shown to be a hallmark of FL. Mutations in histone-modifying genes are likely early, driver events in FL pathogenesis, and so are attractive targets to drug. Gain-of-function mutations in the histone methyltransferase EZH2 are common in FL and maintained through disease evolution. With mounting data supporting a critical role for EZH2 as an oncogenic driver for FL, the small molecule inhibitor, tazemetostat, was developed. Tazemetostat has shown promising activity in preclinical models and early phase trials. Importantly, responses were seen in patients with high-risk features. Based on these data, tazemetostat was approved in the US in 2020 for EZH2
Identifiants
pubmed: 35250278
doi: 10.2147/OTT.S267011
pii: 267011
pmc: PMC8893153
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
193-199Informations de copyright
© 2022 Raychaudhuri and Ujjani.
Déclaration de conflit d'intérêts
CU reports consulting for Epizyme, AbbVie, Atara, Pharmacyclics, Gilead, Janssen, Beigene, Lilly, and Incyte. The authors report no other conflicts of interest in this work.
Références
Clin Cancer Res. 2020 Jul 1;26(13):3145-3153
pubmed: 32122924
Cancer Res. 2016 Jan 15;76(2):275-82
pubmed: 26567139
J Clin Oncol. 2015 Aug 10;33(23):2516-22
pubmed: 26124482
Nature. 2011 Jul 27;476(7360):298-303
pubmed: 21796119
Chem Biol. 2013 Nov 21;20(11):1329-39
pubmed: 24183969
Nature. 2012 Dec 6;492(7427):108-12
pubmed: 23051747
J Biomol Screen. 2012 Dec;17(10):1279-92
pubmed: 22904200
Nature. 2011 Jan 20;469(7330):343-9
pubmed: 21248841
Nature. 2014 Jan 23;505(7484):495-501
pubmed: 24390350
Trends Cancer. 2020 Jul;6(7):580-592
pubmed: 32610068
Nature. 2015 Nov 12;527(7577):249-53
pubmed: 26503055
J Clin Oncol. 2021 May 20;39(15):1609-1618
pubmed: 33683917
Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21360-5
pubmed: 23236167
Eur J Cancer. 2021 Nov;157:132-139
pubmed: 34508995
Cell Rep. 2018 Jun 12;23(11):3262-3274
pubmed: 29898397
Lancet Oncol. 2020 Nov;21(11):1433-1442
pubmed: 33035457
Blood. 2018 Feb 8;131(6):595-604
pubmed: 29158360
Cancer Cell. 2013 May 13;23(5):677-92
pubmed: 23680150
Blood. 2013 Feb 28;121(9):1604-11
pubmed: 23297126
Blood. 2013 Oct 31;122(18):3165-8
pubmed: 24052547
Epigenetics. 2017 May 4;12(5):370-377
pubmed: 28106467
Am J Hematol. 2018 Feb;93(2):296-305
pubmed: 29314206
Lancet Oncol. 2018 May;19(5):649-659
pubmed: 29650362
J Clin Oncol. 2019 Apr 10;37(11):912-922
pubmed: 30742566
Mol Cancer Ther. 2014 Apr;13(4):842-54
pubmed: 24563539
Am J Clin Exp Urol. 2019 Apr 25;7(2):85-91
pubmed: 31139703
Chem Biol. 2014 Nov 20;21(11):1463-75
pubmed: 25457180
CA Cancer J Clin. 2016 Nov 12;66(6):443-459
pubmed: 27618563
Proc Natl Acad Sci U S A. 2015 Mar 10;112(10):E1116-25
pubmed: 25713363
Lancet Oncol. 2021 May;22(5):678-689
pubmed: 33848462
N Engl J Med. 2014 Mar 13;370(11):1008-18
pubmed: 24450858
Clin Cancer Res. 2021 Jun 24;:
pubmed: 34168051
Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:187-207
pubmed: 28992434
J Clin Invest. 2013 Dec;123(12):5009-22
pubmed: 24200695
Nat Genet. 2010 Feb;42(2):181-5
pubmed: 20081860
Cancer Sci. 2021 Sep;112(9):3627-3635
pubmed: 34159682
Br J Haematol. 2019 Feb;184(4):660-663
pubmed: 29611177
Cancer Cell. 2020 May 11;37(5):655-673.e11
pubmed: 32396861
Cancer Sci. 2021 Mar;112(3):1123-1131
pubmed: 33492746